From the Departments of Psychiatry and Human Behavior (Uebelacker, Pinkston, Caviness, Herman, Abrantes) and Family Medicine (Uebelacker, Weisberg), Alpert Medical School of Brown University; Behavioral Medicine and Addictions Research (Uebelacker, Anderson, Caviness, Herman, Abrantes, Stein), Butler Hospital; Department of Medicine (Pinkston), Alpert Medical School of Brown University; Lifespan Physicians Group (Pinkston), The Miriam Hospital, Providence, Rhode Island; Department of Medicine (Busch, Baker), Hennepin Healthcare; Department of Medicine (Busch, Baker), University of Minnesota, Minneapolis, Minnesota; VA Boston Healthcare System (Weisberg); Department of Psychiatry (Weisberg), Boston University School of Medicine; and Department of Health Law, Policy and Management(Stein), Boston University School of Public Health, Boston, Massachusetts.
Psychosom Med. 2023 Apr 1;85(3):250-259. doi: 10.1097/PSY.0000000000001172. Epub 2023 Feb 3.
This study aimed to determine whether HIV-Pain and Sadness Support (HIV-PASS), a collaborative behavioral health intervention based on behavioral activation, is associated with decreased pain-related interference with daily activities, depression, and other outcomes in people living with HIV.
We conducted a three-site clinical trial ( n = 187) in which we randomly assigned participants to receive either HIV-PASS or health education control condition. In both conditions, participants received seven intervention sessions, comprising an initial in-person joint meeting with the participant, their HIV primary care provider and a behavioral health specialist, and six, primarily telephone-based, meetings with the behavioral health specialist and participant. The intervention period lasted 3 months, and follow-up assessments were conducted for an additional 9 months.
Compared with health education, HIV-PASS was associated with significantly lower pain-related interference with daily activities at the end of month 3 (our primary outcome; b = -1.31, 95% confidence interval = -2.28 to -0.34). We did not observe other differences between groups at 3 months in secondary outcomes that included worst or average pain in the past week, depression symptoms, anxiety, and perceived overall mental and physical health. There were no differences between groups on any outcomes at 12 months after enrollment.
A targeted intervention can have positive effects on pain interference. At the end of intervention, effects we found were in a clinically significant range. However, effects diminished once the intervention period ended.
ClinicalTrials.gov NCT02766751.
本研究旨在确定基于行为激活的合作行为健康干预措施 HIV-Pain 和 Sadness Support(HIV-PASS)是否与减轻 HIV 感染者的疼痛相关活动障碍、抑郁等结果相关。
我们进行了一项三站点临床试验(n=187),随机分配参与者接受 HIV-PASS 或健康教育对照条件。在两种情况下,参与者都接受了七次干预会议,包括与参与者、他们的 HIV 初级保健提供者和行为健康专家的初始联合面对面会议,以及六次主要基于电话的与行为健康专家和参与者的会议。干预期持续 3 个月,随后进行了额外 9 个月的随访评估。
与健康教育相比,HIV-PASS 在 3 个月时与疼痛相关的日常活动障碍显著降低(我们的主要结局;b=-1.31,95%置信区间=-2.28 至-0.34)。我们没有在 3 个月时观察到其他次要结局(包括过去一周的最痛或平均疼痛、抑郁症状、焦虑和整体心理和身体健康的感知)存在组间差异。在招募后 12 个月,两组在任何结局上均无差异。
有针对性的干预措施可以对疼痛障碍产生积极影响。在干预结束时,我们发现的效果处于临床显著范围内。然而,一旦干预期结束,效果就会减弱。
ClinicalTrials.gov NCT02766751。